Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 8/20 | 0.48 |
| ▸ | KLK5 | Q9Y337 | 6/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.44 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.44 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.42 |
| ▸ | DAGLA | Q9Y4D2 | 2/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6969013 | 1.00 | KLK7 (0.48) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL3728443 | 0.91 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL19419776 | 0.91 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL15383781 | 0.91 | KLK7 (0.51) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL5888448 | 0.90 | YAP1 (0.47) | KLK7PARP1KMT2A | |
| SCHEMBL5888451 | 0.90 | YAP1 (0.47) | KLK7PARP1KMT2A | |
| SCHEMBL598705 | 0.87 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL598704 | 0.87 | KLK7 (0.45) | KLK7KLK5PRSS1PRSS2PRSS3 | |
| SCHEMBL5966655 | 0.87 | HCRTR1 (0.42) | KLK7STSKMT2A | |
| SCHEMBL247530 | 0.85 | KLK7 (0.54) | KLK7KLK5PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-4069366-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685734-B2 | ATM kinase inhibitors and compositions and methods of use thereof | ATM, CHEK2, CHEK1 | KLK7 2147/4885KLK5 2321/4885PRSS1 2979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.